{"entity":{"id":"nct06694480","kind":"trial","name":"Study of FID-022 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of FID-022 run by Fulgent Pharma LLC., now recruiting.","summary":"Study of FID-022 in Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06694480 by Fulgent Pharma LLC., with 24 participants planned, started 2025-07-03. Conditions recorded: Advanced Solid Tumors. Interventions recorded: FID-022.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06694480","url":"https://clinicaltrials.gov/study/NCT06694480"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["fid-022"],"companies":["fulgent-genetics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06694480","phase":"1","setting":"A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Fulgent Pharma LLC.","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06694480/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fid-022","kind":"drug","name":"FID-022","route":"/drugs/fid-022/"}],"company":[{"id":"fulgent-genetics","kind":"company","name":"Fulgent Genetics","route":"/companies/fulgent-genetics/"}]}}